Prostate cancer: correlation of intravoxel incoherent motion MR parameters with Gleason score

Introduction: Prostate cancer (PCa) staging is an integral part in the management of prostate cancer. The gold standard for diagnosing lymph node invasion is a surgical lymphadenectomy, with no superior imaging modality available at the clinician’s disposal. Our aim in this study is to identify if a pre-biopsy multiparametric MRI (mpMRI) can provide enough information about pelvic lymph nodes in intermediate and high risk PCa patients, and whether it can substitute further cross sectional imaging (CSI) modalities of the abdomen and pelvis in these risk categories. Methods: Patients with intermediate and high risk prostate cancer were collected between January 2015 and June 2019, while excluding patients who did not undergo a pre-biopsy mpMRI or a CSI. Date regarding biopsy result, PSA, MRI results, CSI imaging results were collected. Using Statistical Package for the Social Sciences (SPSS) version 24.0, statistical analysis was conducted using the Cohen’s Kappa agreement for comparison of mpMRI with CSI. McNemar’s test and receiver operator curve (ROC) curve were used for comparison of sensitivity of both tests when comparing to the gold standard of lymphadenectomy. Results: A total of 143 patients fit the inclusion criteria. We further stratified our patients into according to PSA level and Gleason score. Overall, agreement between mpMRI and all CSI was 0.857. When stratifying patients based on Gleason score and PSA, the higher the grade or PSA, the higher agreement between mpMRI and CSI. The sensitivity of mpMRI (73.7%) is similar to CSI (68.4%). When comparing CSI sensitivity to that of mpMRI, no significant difference was present by utilizing the McNemar test and very similar receiver operating characteristic curve. Conclusion: A pre-biopsy mpMRI can potentially substitute further cross sectional imaging in our cohort of patients. However, larger prospective studies are needed to confirm our findings.

Download Full-text

Hypoxia-Inducible Factor 2a Expression Is Positively Correlated With Gleason Score in Prostate Cancer

Technology in Cancer Research & Treatment ◽

10.1177/1533033821990010 ◽

2021 ◽

Vol 20 ◽

pp. 153303382199001

Author(s):

Dimitrios Pavlakis ◽

Spyridon Kampantais ◽

Konstantinos Gkagkalidis ◽

Victoras Gourvas ◽

Dimitrios Memmos ◽

...

Keyword(s):

Prostate Cancer ◽

Gleason Score ◽

Locally Advanced ◽

Hypoxia Inducible Factor ◽

Immunohistochemical Expression ◽

Locally Advanced Prostate Cancer ◽

Grade Group ◽

Main Factors ◽

Hif Pathway ◽

Lower Expression

Background: One of the main factors in response to hypoxia in the tumor microenvironment is the hypoxia-inducible factor (HIF) pathway. Although its role in other solid tumors, particularly renal cell carcinoma, has been sufficiently elucidated, it remains elusive in prostate cancer. The aim of the present study was to investigate the expression of main proteins involved in this pathway and determine the correlation of the results with clinicopathological outcomes of patients with prostate cancer. Methods: The immunohistochemical expression of HIF-1a, HIF-2a and their regulators, prolyl hydroxylase domain (PHD)1, PHD2 and PHD3 and factor inhibiting HIF (FIH), was assessed on a tissue microarray. This was constructed from radical prostatectomy specimens, involving both tumor and corresponding adjacent non-tumoral prostate tissues from 50 patients with localized or locally advanced prostate cancer. Results: In comparison with non-tumoral adjacent tissue, HIF-1a exhibited an equal or lower expression in 86% of the specimens (P = 0.017), while HIF-2a was overexpressed in 52% (P = 0.032) of the cases. HIF-1a protein expression was correlated with HIF-2a (P < 0.001), FIH (P = 0.004), PHD1 (P < 0.001), PHD2 (P < 0.001) and PHD3 (P = 0.035). HIF-2a expression was positively correlated with Gleason score (P = 0.017) and International Society of Urological Pathologists (ISUP) grade group (P = 0.022). Conclusions: The findings of the present study suggest a key role for HIF-2a in prostate cancer, as HIF-2a expression was found to be correlated with Gleason score and ISUP grade of the patients. However, further studies are required to validate these results and investigate the potential value of HIF-2a as a therapeutic target in prostate cancer.

Download Full-text

Formal methods for prostate cancer Gleason score and treatment prediction using radiomic biomarkers

Magnetic Resonance Imaging ◽

10.1016/j.mri.2019.08.030 ◽

2020 ◽

Vol 66 ◽

pp. 165-175 ◽

Cited By ~ 10

Author(s):

Luca Brunese ◽

Francesco Mercaldo ◽

Alfonso Reginelli ◽

Antonella Santone

Keyword(s):

Prostate Cancer ◽

Formal Methods ◽

Gleason Score ◽

Treatment Prediction

Download Full-text

Polygenic hazard score is associated with prostate cancer in multi-ethnic populations

Nature Communications ◽

10.1038/s41467-021-21287-0 ◽

2021 ◽

Vol 12 (1) ◽

Author(s):

Minh-Phuong Huynh-Le ◽

◽

Chun Chieh Fan ◽

Roshan Karunamuni ◽

Wesley K. Thompson ◽

...

Keyword(s):

Prostate Cancer ◽

Health Disparities ◽

Gleason Score ◽

Cancer Diagnosis ◽

Distant Metastasis ◽

Ethnic Populations ◽

Hazard Ratios ◽

Aggressive Cancer ◽

Screening Accuracy ◽

Fatal Prostate Cancer

AbstractGenetic models for cancer have been evaluated using almost exclusively European data, which could exacerbate health disparities. A polygenic hazard score (PHS1) is associated with age at prostate cancer diagnosis and improves screening accuracy in Europeans. Here, we evaluate performance of PHS2 (PHS1, adapted for OncoArray) in a multi-ethnic dataset of 80,491 men (49,916 cases, 30,575 controls). PHS2 is associated with age at diagnosis of any and aggressive (Gleason score ≥ 7, stage T3-T4, PSA ≥ 10 ng/mL, or nodal/distant metastasis) cancer and prostate-cancer-specific death. Associations with cancer are significant within European (n = 71,856), Asian (n = 2,382), and African (n = 6,253) genetic ancestries (p < 10−180). Comparing the 80th/20th PHS2 percentiles, hazard ratios for prostate cancer, aggressive cancer, and prostate-cancer-specific death are 5.32, 5.88, and 5.68, respectively. Within European, Asian, and African ancestries, hazard ratios for prostate cancer are: 5.54, 4.49, and 2.54, respectively. PHS2 risk-stratifies men for any, aggressive, and fatal prostate cancer in a multi-ethnic dataset.

Download Full-text